Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 6/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | NT5E | P21589 | 4/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889018 | 0.92 | YTHDC1 (0.35) | PIK3CAYTHDC1HDAC1FLT3ATR | |
| SCHEMBL19206330 | 0.81 | YTHDC1 (0.39) | YTHDC1HDAC1FLT3ATRHRH3 | |
| SCHEMBL2673005 | 0.81 | YTHDC1 (0.41) | YTHDC1HDAC1FLT3ATRHRH3 | |
| SCHEMBL9936995 | 0.81 | HDAC1 (0.40) | YTHDC1HDAC1FLT3ATRHRH3 | |
| SCHEMBL30471263 | 0.81 | HDAC1 (0.40) | YTHDC1HDAC1FLT3ATRHRH3 | |
| SCHEMBL30471093 | 0.80 | YTHDC1 (0.38) | PIK3CAYTHDC1HDAC1FLT3ATR | |
| SCHEMBL2113717 | 0.80 | YTHDC1 (0.38) | PIK3CAYTHDC1HDAC1FLT3ATR | |
| SCHEMBL1114173 | 0.79 | PIK3CD (0.40) | PIK3CAYTHDC1HDAC1FLT3ATR | |
| SCHEMBL9937975 | 0.79 | YTHDC1 (0.38) | YTHDC1HDAC1FLT3ATRHRH3 | |
| SCHEMBL31372903 | 0.79 | PIK3CD (0.40) | PIK3CAYTHDC1HDAC1FLT3ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | PIK3CA 3/4885YTHDC1 4766/4885HDAC1 445/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | PIK3CA 1/4885YTHDC1 4755/4885HDAC1 298/4885 |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | PIK3CA 3/4885YTHDC1 4766/4885HDAC1 445/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | PIK3CA 1/4885YTHDC1 4755/4885HDAC1 298/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | PIK3CA 10/4885YTHDC1 3570/4885HDAC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.